JP7254350B2 - β－１，６－グルカン治療用抗体コンジュゲート - Google Patents

β－１，６－グルカン治療用抗体コンジュゲート Download PDF

Info

Publication number
JP7254350B2
JP7254350B2 JP2019531127A JP2019531127A JP7254350B2 JP 7254350 B2 JP7254350 B2 JP 7254350B2 JP 2019531127 A JP2019531127 A JP 2019531127A JP 2019531127 A JP2019531127 A JP 2019531127A JP 7254350 B2 JP7254350 B2 JP 7254350B2
Authority
JP
Japan
Prior art keywords
glucan
antibody
cetuximab
oligomers
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019531127A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020510622A (ja
JP2020510622A5 (https=
Inventor
ガブリエル オスカー レズニック，
ジョン ジェイムズ ケーン，
ジェイムズ マイケル シェドレツキ，
ズザーナ ドスタロバ，
イザベル サンサル－カステリャーノ，
イファト ルビン－ベイェラノ，
フア ミアオ，
エリック スティーブン ファーフィン，
Original Assignee
イネイト バイオセラピューティクス， エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イネイト バイオセラピューティクス， エルエルシー filed Critical イネイト バイオセラピューティクス， エルエルシー
Publication of JP2020510622A publication Critical patent/JP2020510622A/ja
Publication of JP2020510622A5 publication Critical patent/JP2020510622A5/ja
Application granted granted Critical
Publication of JP7254350B2 publication Critical patent/JP7254350B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2019531127A 2016-12-07 2017-12-05 β－１，６－グルカン治療用抗体コンジュゲート Active JP7254350B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662431362P 2016-12-07 2016-12-07
US62/431,362 2016-12-07
PCT/US2017/064631 WO2018106645A1 (en) 2016-12-07 2017-12-05 β-1,6-GLUCAN THERAPEUTIC ANTIBODY CONJUGATES

Publications (3)

Publication Number Publication Date
JP2020510622A JP2020510622A (ja) 2020-04-09
JP2020510622A5 JP2020510622A5 (https=) 2021-02-18
JP7254350B2 true JP7254350B2 (ja) 2023-04-10

Family

ID=62492341

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019531127A Active JP7254350B2 (ja) 2016-12-07 2017-12-05 β－１，６－グルカン治療用抗体コンジュゲート

Country Status (4)

Country Link
US (1) US11865135B2 (https=)
EP (1) EP3582810A4 (https=)
JP (1) JP7254350B2 (https=)
WO (1) WO2018106645A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018106645A1 (en) 2016-12-07 2018-06-14 Innate Biotherapeutics, Llc β-1,6-GLUCAN THERAPEUTIC ANTIBODY CONJUGATES
CN113512116B (zh) * 2020-04-10 2022-09-20 苏州普乐康医药科技有限公司 一种抗igf-1r抗体及其应用
CN118475372A (zh) * 2021-10-29 2024-08-09 博尔特生物治疗药物有限公司 具有半胱氨酸突变抗体的tlr激动剂免疫缀合物及其用途
WO2023161528A1 (en) * 2022-02-28 2023-08-31 Tridem Bioscience Gmbh & Co Kg A CONJUGATE COMPRISING AT LEAST A ß-GLUCAN

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011519049A (ja) 2008-04-29 2011-06-30 イミューンエクサイト インコーポレイテッド 免疫調節組成物およびその使用方法
WO2016118654A1 (en) 2015-01-20 2016-07-28 Immunexcite, Inc. Compositions and methods for cancer immunotherapy
WO2016196682A1 (en) 2015-06-01 2016-12-08 Immunexcite, Inc. β-1,6-GLUCAN CETUXIMAB ANTIBODY CONJUGATES

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004030613A2 (en) 2002-09-04 2004-04-15 University Of Louisville Research Foundation, Inc. Cancer therapy using beta glucan and antibodies
US8048432B2 (en) * 2003-08-06 2011-11-01 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Polysaccharide-protein conjugate vaccines
US7070778B2 (en) 2003-10-30 2006-07-04 Laboratoire Goemar Sa Therapeutical combination against cancer
FR2944448B1 (fr) 2008-12-23 2012-01-13 Adocia Composition pharmaceutique stable comprenant au moins un anticorps monodonal et au moins un polysacharide amphiphile comprenant des substituants derives d'alcools hydrofobes ou d'amines hydrophobes.
US20120288495A1 (en) 2009-07-22 2012-11-15 Biothera, Inc. Therapeutic compositions and methods
WO2012154818A1 (en) 2011-05-09 2012-11-15 Biothera, Inc. B-glucan compounds, compositions, and methods
KR102447350B1 (ko) * 2013-02-08 2022-09-23 노파르티스 아게 면역접합체의 제조를 위한 항체의 변형에 사용되는 특정 부위
AU2015255823A1 (en) 2014-05-08 2016-11-10 Immunexcite, Inc. Immunomodulating beta-1,6-D-glucans
WO2018106644A1 (en) 2016-12-07 2018-06-14 Innate Biotherapeutics, Llc ß-1,6-GLUCAN TRASTUZUMAB ANTIBODY CONJUGATES
WO2018106645A1 (en) 2016-12-07 2018-06-14 Innate Biotherapeutics, Llc β-1,6-GLUCAN THERAPEUTIC ANTIBODY CONJUGATES

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011519049A (ja) 2008-04-29 2011-06-30 イミューンエクサイト インコーポレイテッド 免疫調節組成物およびその使用方法
WO2016118654A1 (en) 2015-01-20 2016-07-28 Immunexcite, Inc. Compositions and methods for cancer immunotherapy
WO2016196682A1 (en) 2015-06-01 2016-12-08 Immunexcite, Inc. β-1,6-GLUCAN CETUXIMAB ANTIBODY CONJUGATES

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Cancer Res. (2015) vol.75, no.15, suppl.1, Abstract 4297,<https://cancerres.aacrjournals.org/content/75/15_Supplement/4297>
J. Immunother. Cancer (2014) vol.2, suppl.3, P262
J. Immunother. Cancer (2015) vol.3, suppl.2, P414

Also Published As

Publication number Publication date
US20200030360A1 (en) 2020-01-30
JP2020510622A (ja) 2020-04-09
EP3582810A4 (en) 2020-08-19
EP3582810A1 (en) 2019-12-25
US11865135B2 (en) 2024-01-09
WO2018106645A1 (en) 2018-06-14

Similar Documents

Publication Publication Date Title
TWI841715B (zh) 抗體-吡咯并苯二氮呯衍生物結合物及ｐａｒｐ抑制劑之組合及其用途
JP6770535B2 (ja) Ｃｄ１２３抗体及びその複合体
RU2766586C2 (ru) Фармацевтическая композиция для лечения и/или предупреждения злокачественной опухоли
US20220177601A1 (en) Anti-her2 antibody-pyrrolobenzodiazepine derivative conjugate
JP7254350B2 (ja) β－１，６－グルカン治療用抗体コンジュゲート
WO2021248048A9 (en) Antibody-drug conjugates containing an anti-mesothelin antibody and uses thereof
JP2021513844A (ja) グリピカン３抗体およびそのコンジュゲート
JP2019521106A (ja) 抗ｅｇｆｒ抗体薬物コンジュゲート
CN116173232A (zh) 抗cd98抗体及抗体药物偶联物
AU2020338481A1 (en) Targeted dendrimer conjugates
US20180154014A1 (en) Beta-1,6-glucan cetuximab antibody conjugates
KR20200124701A (ko) 항―ｐｄ－１ 항체 및 그의 용도
CN113227142A (zh) 抗pd-1抗体及其用途
CN115052632A (zh) 靶向多肽-药物缀合物及其用途
JP2019536811A (ja) β−１，６−グルカンのトラスツズマブ抗体コンジュゲート
WO2025015281A1 (en) De-n-acetylated polysialic acid (dpsa) binding agent, conjugates, and method of using same
CN119490559A (zh) 化合物以及含有该化合物的抗体偶联药物
EP4501967A1 (en) Ph-dependent anti-sulfated glycosaminoglycan antibody and antibody-drug conjugate
KR20260053355A (ko) 화합물 및 이를 포함하는 항체 약물 접합체
CN121868507A (zh) 抗EGFR和cMET双特异性抗体的抗体药物偶联物
HK40123051A (zh) 化合物以及含有该化合物的抗体偶联药物
CN120899896A (zh) 药物组合及其用途
KR20250115918A (ko) 항체-약물 접합체 제조를 위한 새로운 캄토테신 유도체-링커 화합물
CN121127268A (zh) 抗体药物偶联物在制备预防和/或治疗癌症的药物中的用途
HK40067376A (en) Combination of antibody-pyrrolobenzodiazepine derivative conjugate and parp inhibitor

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201207

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201207

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20201207

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201217

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210120

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211026

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220120

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220614

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220809

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221213

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230222

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230322

R150 Certificate of patent or registration of utility model

Ref document number: 7254350

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150